首页> 外文学位 >Characterization of the anti-tumor properties of IDN 5390, a novel seco-taxane derivative.
【24h】

Characterization of the anti-tumor properties of IDN 5390, a novel seco-taxane derivative.

机译:新型癸二烷衍生物IDN 5390的抗肿瘤特性的表征。

获取原文
获取原文并翻译 | 示例

摘要

Protracted low dose administration of conventional chemotherapeutic agents ("metronomic dosing"), including the taxanes paclitaxel and docetaxel, has been shown to inhibit tumor growth by an anti-angiogenic mechanism. The feasibility of these two clinical agents for protracted scheduling is limited, however, by host toxicity and poor oral bioavailibility. IDN-5390 is a novel secotaxane derivative with improved oral bioavailability and a toxicity profile suitable for daily administration, rendering it an excellent candidate for metronomic dosing in vivo to achieve an anti-angiogenic effect.; While the mechanism of anti-angiogenic effect of taxanes has been primarily attributed to endothelial cell cytotoxicity, studies on HUVEC (human umbilical vein endothelial cells) also demonstrate potent inhibition of endothelial motility. Furthermore, inhibition of cellular motility is observed at non-cytotoxic concentrations of IDN 5390, suggesting a selectivity in mechanism of action of this taxane analog. Multiple techniques for the evaluation of endothelial cell migration were employed to test this hypothesis. In a modified Boyden chamber migration assay, IDN-5390 inhibited HUVEC chemotaxis in a dose-dependent manner at concentrations that did not compromise cell viability. A HUVEC monolayer "wounding" assay, in which cell migration into a denuded area of a cell monolayer was monitored by time-lapse video microscopy, also demonstrated inhibition of endothelial cell motility at non-toxic doses. Although more potent inhibitors of cell growth, paclitaxel and docetaxel did not exhibit selectivity for inhibition of cell migration in these studies.; Further evaluation of these agents revealed that paclitaxel, docetaxel and IDN 5390 all potently polymerize purified tubulin in vitro, but IDN 5390 did not stabilize microtubules against depolymerization as potently as paclitaxel or docetaxel, suggesting that the dynamic instability of microtubules may be differentially regulated in a cellular context. Indeed, treatment of HUVEC with IDN 5390, even at high concentrations, causes an arrest of the cells in G2/M that is transient; in contrast, paclitaxel and docetaxel induced G2/M arrest to an overall greater extent than IDN 5390 and this arrest was sustained. An increase in apoptosis was also correlated with cell cycle arrest, with paclitaxel and docetaxel treatment resulting in an increase in HUVEC apoptosis, while significantly less apoptosis was observed with IDN 5390 treatment. (Abstract shortened by UMI.)
机译:已经显示,包括紫杉烷类紫杉醇和多西紫杉醇的常规化学治疗剂的长期低剂量给药(“计量给药”)通过抗血管生成机制抑制肿瘤的生长。但是,这两种临床药物用于延长排程的可行性受到宿主毒性和不良口服生物利用度的限制。 IDN-5390是一种新型的紫杉烷衍生物,具有改善的口服生物利用度和适于日常给药的毒性特征,使其成为体内进行节律给药以达到抗血管生成作用的极佳候选者。虽然紫杉烷类的抗血管生成作用的机理主要归因于内皮细胞的细胞毒性,但是对HUVEC(人脐静脉内皮细胞)的研究也显示出对内皮运动的有效抑制。此外,在非细胞毒性的IDN 5390浓度下观察到细胞运动的抑制,表明该紫杉烷类似物的作用机理具有选择性。多种评估内皮细胞迁移的技术被用来检验这一假设。在改良的博登室迁移试验中,IDN-5390在不损害细胞生存力的浓度下以剂量依赖性方式抑制HUVEC趋化性。 HUVEC单层“伤口”测定法(其中通过延时视频显微镜监测细胞迁移到单层细胞的裸露区域)也证明了在无毒剂量下内皮细胞的运动受到抑制。尽管在这些研究中,更有效的细胞生长抑制剂,紫杉醇和多西紫杉醇对抑制细胞迁移没有选择性。对这些药物的进一步评估表明,紫杉醇,多西紫杉醇和IDN 5390均能在体外有效地聚合纯化的微管蛋白,但IDN 5390不能像紫杉醇或多西紫杉醇那样稳定微管使其免受解聚作用,这表明微管的动态不稳定性可能会受到不同程度的调节。细胞环境。实际上,即使在高浓度下,用IDN 5390处理HUVEC也会导致G2 / M细胞暂时停滞。相反,紫杉醇和多西紫杉醇引起的G2 / M阻滞比IDN 5390总体上更大,并且这种阻滞得以持续。凋亡的增加也与细胞周期停滞有关,紫杉醇和多西他赛治疗导致HUVEC凋亡增加,而IDN 5390处理则观察到明显更少的凋亡。 (摘要由UMI缩短。)

著录项

  • 作者

    Chaudhary, Neeta D.;

  • 作者单位

    State University of New York at Buffalo.;

  • 授予单位 State University of New York at Buffalo.;
  • 学科 Health Sciences Pharmacology.; Health Sciences Oncology.; Biology Cell.
  • 学位 Ph.D.
  • 年度 2006
  • 页码 107 p.
  • 总页数 107
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;肿瘤学;细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号